

Special Issue

Nanotoxicity of Drug Delivery Systems for Cancer Therapy

Message from the Guest Editor

Benefiting from the rapid advancement of nanotechnology, nanoparticles have emerged as a pivotal strategy for improving the drug delivery of anticancer drugs. The utilization of nanoscale drug delivery systems holds the potential to enhance drug accumulation, penetration, and targeted uptake within tumor tissues while also enabling controlled drug release. With the widening array of nanomaterials integrated into drug delivery systems, concerns regarding nanotoxicity have gained prominence. The interplay between nanomaterials, distinguished by their nanoscale dimensions, and biological tissue, cells, and microenvironments can expose adverse effects. However, despite the widespread use of nanomedicines, our understanding of the toxicity they may induce remains constrained. This Special Issue aims to publish high-quality research papers and reviews focusing on recent advances, outcomes, and correlations between toxicity and nanomaterial-based drug delivery systems for cancer therapy, ranging from understanding cellular toxicity, whole animal toxicity, neurotoxicity, immunotoxicity, genotoxicity, and population-scale effects.

Guest Editor

Dr. Ilya Yakavets

Department of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada

Deadline for manuscript submissions

closed (29 February 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/184359

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).